Microvascular Therapeutics to Present Late-Breaking Clinical Data on CardiSon™ (MVT-100) at the 2026 American Society of Echocardiography Meeting. - PR.com
Summary
Microvascular Therapeutics will present late-breaking clinical data on CardiSon (MVT-100) at the 2026 ASE Scientific Sessions. The study reports better left ventricular opacification and less acoustic shadowing than Definity, along with a favorable safety profile. The company says the product is moving toward pivotal clinical development and regulatory approval. The release also highlights preclinical advantages in stability, storage flexibility, and renal retention. These results position CardiSon as a potential next-generation contrast agent for echocardiography.
Classifications
industries
No industries detected
applications
No applications detected
AI Classifications
Labels
No AI classifications detected